Medispar SA
4.1 FTEMedispar reported total assets of €2.72m at the end of the 2025 financial year (annual accounts filed with the NBB on 23 Jun 2026), with 4.1 full-time equivalents.
The score of Medispar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -67 % Total assets -46 % Headcount (avg FTE) +78 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Medispar's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jun 2026
- Year ended 31 Dec 2024filed on 30 Jul 2025
- Year ended 31 Dec 2023filed on 20 Jul 2024
- Year ended 31 Dec 2022filed on 02 Jun 2023
- Year ended 31 Dec 2021filed on 01 Jul 2022
Medispar's financial analysis
- Solvency17.3%sector median: 33.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Medispar
Medispar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0875.667.302
- VAT number
- BE0875667302
- Peppol
- Registered · 0208:0875667302 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 23 Aug 2005
- Registered office
- 1000 Brussels
- Size
- Micro · 4.1 FTE
- Latest accounts
- 2025 · filed on 23 Jun 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Medispar (SA) has been based in Brussels since 2005, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net loss of €1.16m and equity of 471,959 €; its revenue is not published. With 4.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 17.3%, below the median of its sector (33.7%).
Companies similar to Medispar
Companies in the same business, of comparable size and area, outside its group.
- Hospiplan Wholesale of pharmaceutical and medical goods Schaerbeek · balance sheet €5.29m
- PRO Scan Manufacture of medical and dental instruments and supplies Zonhoven · balance sheet €2.83m
- Motion Medical Holding Manufacture of medical and dental instruments and supplies Les Bons Villers · balance sheet €4.44m
- Meditor Benelux Wholesale of pharmaceutical and medical goods Brussels · balance sheet 735,858 €
- Dentalbiolux International Wholesale of pharmaceutical and medical goods Schaerbeek · balance sheet €1.37m
- Hasa Optix Wholesale of pharmaceutical and medical goods Ixelles · balance sheet €1.29m
- Pharmentum Manufacture of pharmaceutical preparations Kontich · balance sheet €1.94m
- OMC Wholesale of pharmaceutical and medical goods Kortrijk · balance sheet €2.75m
Frequently asked questions about Medispar
What is the revenue of Medispar?
Medispar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Medispar?
In Belgium, the VAT number is the company number prefixed with BE: BE0875667302 for Medispar, if the company is VAT-registered. Its company number (CBE) is 0875.667.302.
Where is the registered office of Medispar?
According to the CBE register, the registered office of Medispar is in 1000 Brussels.
What is the equity of Medispar?
At the close of the 2025 financial year, the equity of Medispar amounts to 471,959 €, a solvency of 17.3% of total assets.
How many people work at Medispar?
4.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Medispar?
The register lists 2 active mandates at Medispar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Medispar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →